ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

48,42
-0,81
(-1,65%)
Fermé 06 Juin 10:00PM
48,42
0,045
(0,09%)
Après les heures de négociation: 1:59AM

Kiniksa Pharmaceuticals International PLC (KNSA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
48,42
( -1,65% )
Prix Achat
46,09
Prix Vente
48,69
Volume échangé
344 593
48,21 Fourchette du Jour 49,9899
26,27 Plage de 52 semaines 59,87
Cap du marché
Clôture Veille
49,23
Ouverture
48,98
Dernière Transaction
8
@
47.66
Dernière heure de transaction
Volume financier
US$ 16 796 069
VWAP
48,7418
Volume moyen (3 m)
US$ 702 643
Actions en circulation
76 938 016
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
53,3
Bénéfice par action (BPA)
0,91
Chiffre d'affairess (LTM)
754,05M
Bénéfice net (LTM)
73,06M

À propos de Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
London, United Kingdom
Fondé
2026
Kiniksa Pharmaceuticals International PLC est coté dans le secteur Healthcare de la NASDAQ avec le ticker KNSA. Le dernier cours de clôture d'Kiniksa Pharmaceuticals était de US$49,23. Au cours de la dernière année, les actions de Kiniksa Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 26,27 à US$ 59,87.

Kiniksa Pharmaceuticals compte actuellement 76 938 016 actions en circulation. La capitalisation boursière d'Kiniksa Pharmaceuticals est de US$3,73 milliard. Kiniksa Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de 53.30.

KNSA Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.3-4.5347003154650.7250.846.100461702248.13098766CS
4-8.64-15.14195583657.0659.8746.100452245952.87236642CS
121.934.1514304151446.4959.8741.4968085149.5540811CS
267.317.752918287941.1259.8737.0262944846.44341388CS
5219.6668.358831710728.7659.8726.2761119939.82375887CS
15633.93234.16149068314.4959.8713.5550832128.18772398CS
26035.07262.69662921313.3559.877.3645603522.9713684CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals International PLC share price?
The current share price of Kiniksa Pharmaceuticals International PLC is US$ 48,42
How many Kiniksa Pharmaceuticals International PLC shares are in issue?
Kiniksa Pharmaceuticals International PLC has 76 938 016 shares in issue
What is the market cap of Kiniksa Pharmaceuticals International PLC?
The market capitalisation of Kiniksa Pharmaceuticals International PLC is USD 3,73B
What is the 1 year trading range for Kiniksa Pharmaceuticals International PLC share price?
Kiniksa Pharmaceuticals International PLC has traded in the range of US$ 26,27 to US$ 59,87 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals International PLC?
The price to earnings ratio of Kiniksa Pharmaceuticals International PLC is 53,3
What is the cash to sales ratio of Kiniksa Pharmaceuticals International PLC?
The cash to sales ratio of Kiniksa Pharmaceuticals International PLC is 4,94
What is the registered address of Kiniksa Pharmaceuticals International PLC?
The registered address for Kiniksa Pharmaceuticals International PLC is 105 Piccadilly, London, Greater London, W1J 7NJ
What is the Kiniksa Pharmaceuticals International PLC website address?
The website address for Kiniksa Pharmaceuticals International PLC is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals International PLC operate in?
Kiniksa Pharmaceuticals International PLC operates in the Biotechnology & Life Sciences sector

KNSA Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock